Browse the evidence

High-dose canagliflozin (300 mg/day) is significantly associated with reduced sepsis risk versus control.

Practitioners may consider high-dose canagliflozin as a safer option regarding sepsis risk.

Treatment duration had minimal influence on primary outcomes.

Practitioners may not need to adjust treatment duration based on infection risk concerns.

The psychiatric side effects resolved with medication cessation.

Discontinuation of GLP-1 RAs may alleviate associated psychiatric symptoms.

Metabolomic subtypes have shown potential in guiding treatment selection for obesity.

Practitioners can consider metabolomic profiles to tailor obesity treatments.

Prolonged and unreasonable use of GLP-1 agonists may lead to undesirable effects.

Healthcare providers should monitor patients for potential adverse effects when using GLP-1 agonists long-term.

The mean four-month weight loss percentage was statistically lower in the compounded Semaglutide group (9.11%) compared to the pure Semaglutide group (9.87%).

Practitioners should be aware that compounded Semaglutide may result in slightly less weight loss compared to pure Semaglutide.

There are significant adverse effects associated with GLP-1 receptor agonists.

Healthcare providers should be aware of the potential adverse effects when prescribing GLP-1 receptor agonists.

There is potential for further applications of GLP-1 receptor agonists outside of type 2 diabetes management.

Further research may reveal additional therapeutic uses for GLP-1 receptor agonists, which could expand treatment options.

Integrating pharmacological, minimally invasive, and genetic strategies may enhance long-term weight management and metabolic outcomes.

Combining different treatment modalities may lead to better results for patients with obesity.

Metformin prescribing was marginally higher (1.6%) among those with BMI ≥35 kg/m2, age <60 years, HbA1c ≥6.0%, or those with a history of gestational diabetes.

Practitioners should consider these factors when prescribing metformin.

Obesity is a leading cause of morbidity and mortality with health consequences that crosscut most medical specialties.

Healthcare providers should recognize the widespread impact of obesity on health.

There are many impediments to comprehensive obesity care despite the emergence of effective therapies.

Clinicians should be aware of and address barriers to effective obesity treatment.

Lifestyle modifications have limited lasting effects on weight and blood pressure reduction.

Practitioners should consider the limited effectiveness of lifestyle changes alone for weight and BP management.

The review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals.

The review may provide insights into the safety profile of these medications for practitioners.

Current pharmacological treatments aim to restore energy balance by targeting disrupted pathways.

Practitioners should be aware of pharmacological options that target energy balance in obesity management.

Categories of weight change did not differ for change in physical activity or dietary intake.

Weight change categories may not influence physical activity or dietary intake adjustments.

Intervention conditions did not differ for change in weight, physical activity, dietary intake, and measures of hunger, dietary disinhibition, and total dietary restraint.

Different physical activity interventions may not lead to significant differences in weight or dietary behaviors.

Rates of obesity have doubled for adults and quadrupled for adolescents since the 1990s.

Practitioners should be aware of the rising obesity rates to address this public health issue.

There needs to be a cultural shift to accept obesity as a disease and improve access to effective treatments sooner.

Advocacy for policy changes and education on obesity as a disease is essential.

Patient factors potentially contributing to increased aspiration risks included a higher body mass index, type 2 diabetes mellitus, gastro-oesophageal reflux disease, emergency case, and time from GLP-1 agonist cessation.

Understanding these risk factors can help clinicians better assess patients on GLP-1 agonists before surgery.

The tolerability and key adverse events associated with these AOMs appear to be acceptable in randomized controlled trials.

Clinicians can be reassured about the safety profile of newer AOMs based on trial data.

The current evidence for interventions that address food insecurity and obesity is mixed and limited in scope.

More rigorous trials are needed to determine effective interventions for obesity in food-insecure populations.

Success in weight loss was independent of the quantity and quality of carbohydrate intake.

Weight loss programs may not need to focus on carbohydrate quantity or quality.

Subjects with the highest scores on the 'high-protein and high-carbohydrate' dietary patterns had higher odds of cardiovascular disease (CVD) than those with the lowest scores (OR: 2.89, 95% CI: 2.11–3.96).

Practitioners should consider advising patients with T2D to be cautious about high-protein and high-carbohydrate dietary patterns due to their association with increased CVD risk.